[Effect of insulin plus rosiglitazone or metformin on serum N-terminal pro-brain natriuretic peptide in type 2 diabetes mellitus: a randomized-controlled study]

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

This study was aimed to compare the effect of insulin plus rosiglitazone with that of insulin plus metformin on the level of serum N-terminal pro-brain natriuretic peptide (NT-BNP) in patients with type 2 diabetes mellitus, and to find out whether serum NT-BNP can be used as an index for predicting heart failure induced by rosiglitazone in the cases of type 2 diabetes mellitus.

Why It Was Studied

The observations covered an 8-weeks' course of treatment.

Who Took Part

According to the abstract, 2 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

Serum NT-BNP was measured at the beginning and at the end of 8 weeks.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin, Metformin, Natriuretic Peptide, Brain, Peptide Fragments and Rosiglitazone.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2008 (Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi), a journal based in China.

More context: the BNP (Nesiritide) compound page, all human trials.